4basebio (LSE:4BB) Debt-to-Equity : 0.00 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is 4basebio Debt-to-Equity?

4basebio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £0.00 Mil. 4basebio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £0.00 Mil. 4basebio's Total Stockholders Equity for the quarter that ended in Jun. 2023 was £3.41 Mil. 4basebio's debt to equity for the quarter that ended in Jun. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for 4basebio's Debt-to-Equity or its related term are showing as below:

LSE:4BB' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.37 Med: 0.13 Max: 0.47
Current: 0.98

During the past 4 years, the highest Debt-to-Equity Ratio of 4basebio was 0.47. The lowest was -1.37. And the median was 0.13.

LSE:4BB's Debt-to-Equity is ranked worse than
86.9% of 1076 companies
in the Biotechnology industry
Industry Median: 0.15 vs LSE:4BB: 0.98

4basebio Debt-to-Equity Historical Data

The historical data trend for 4basebio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Debt-to-Equity Chart

4basebio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

-1.37

0.11

0.15

0.47

4basebio Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial			-	0.15	-	0.47	-

Competitive Comparison of 4basebio's Debt-to-Equity

For the Biotechnology subindustry, 4basebio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4basebio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4basebio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where 4basebio's Debt-to-Equity falls into.

4basebio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

4basebio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.415	+	2.935)	/	7.12
	=	0.47

4basebio's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.411
	=	0.00

4basebio (LSE:4BB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

4basebio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of 4basebio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

4basebio (LSE:4BB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (LSE:4BB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

88Q:Germany

Address

25 Norman Way, Over, Cambridge, GBR, CB24 5QE

Website

https://www.4basebio.com

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (LSE:4BB) Headlines

No Headlines